KRAS and non-small cell lung carcinoma: Large-scale genomic profiling of NSCLC cohorts confirmed that KRAS/STK11 co-mutations define an immunologically “cold” subset with minimal PD-L1 expression and poor response to immune checkpoint inhibitors (56).